Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VIVUS gets two additional US patents from USPTO for Qsymia
The newly issued patents are assigned to VIVUS and will be submitted for listing in the FDA’s Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book) and
The newly issued patents are assigned to VIVUS and will be submitted for listing in the FDA’s Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book) and
PACF partners with local organisations working to improve the health and wellbeing of women and children affected by HIV, and the communities they live in. All PACF projects
Recipharm will significantly expand its pharmaceutical development capacity and technical capabilities to provide easier access for development services to its French and other customers. Recipharm will also provide
In consideration for the Technology, the Company paid to Ms. Arnett and Mr. Hargreaves a total of USD $100,000 and issued to Ms. Arnett and Mr. Hargreaves options
Recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are
The CDP was prepared in collaboration with d3 Medicine and contains detailed plans for all pre-clinical tasks including pharmacology, pharmacokinetics, manufacturing, formulation and toxicology of MetaMx. Arch Biopartners
"We are particularly proud of this filing, as it represents our commitment to YONDELIS and the people it may help," said Peter F. Lebowitz, M.D., Ph.D., Global Oncology
This product is the generic version of BREVIBLOC, which is indicated for supraventricular tachycardia or noncompensatory sinus tachycardia, and intraoperative and postoperative tachycardia and/or hypertension. Mylan believes that
The potential application of E-selectin in the clinic is based on the role that the compound plays in coordinating and responding to the immune system’s activation and resulting
Acne vulgaris is a common skin disorder that affects 40 to 50 million people in the United States. "We are very pleased that the FDA has approved this